Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictors of discordant end-of-treatment PET positivity in advanced-stage classical Hodgkin lymphoma patients with negative interim PET response

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAlaa Hamad

Discussion

Loading...

Member takes

Overview

Retrospective review uncovers metabolic response correlating with residual disease in advanced Hodgkin lymphoma patients, highlighting predictive factors like stage IV disease.

Key Points

  • To identify baseline clinical features predicting discordant end-of-treatment PET positivity in advanced-stage classical Hodgkin lymphoma patients.
  • Retrospective review of 122 patients with advanced-stage classical Hodgkin lymphoma treated with ABVD.
  • Patients achieved complete metabolic response on interim PET after two cycles of treatment.
  • Collected clinical and laboratory data including IPS score, bone marrow involvement, and extranodal disease.
  • 17.2% of patients with negative interim PET had residual uptake on end-of-treatment PET.
  • Stage IV disease was identified as an independent predictor for residual disease at end-of-treatment with an OR of 3.32.
  • Two-year disease-free survival was estimated at 83%.

Cite This Study

Alaa Hamad (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d723https://doi.org/10.1182/blood-2025-7139
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The predictive and prognostic role of baseline 2-[18F]FDG PET/CT volumetric and dissemination features in classical Hodgkin lymphoma2026 · 2 citations
  2. 2Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium2025
  3. 3Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients2024 · 9 citations
  4. 4Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study2025 · 6 citations
  5. 5Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305)2024 · 4 citations